Latest news

• Vifor wins European approval for Veltassa

  cyclosilicate) in February.

• FDA turns down AZ's ZS-9 once again on manufacturing issues

  The US regulator issued a Complete Response Letter to ZS Pharma regarding its application for ZS-9 (sodium zirconium cyclosilicate) as a treatment for the condition - known as hyperkalaemia - after an

• AZ nears EU approval for hyperkalaemia drug Lokelma

  Lokelma (sodium zirconium cyclosilicate) is a potassium-binding compound designed to reduce excessive levels of serum potassium by drawing it into the gastrointestinal tract.

• 2017 set to be a "defining year" for AZ

  and hyperkalaemia candidate sodium zirconium cyclosilicate (ZS-9), which was rejected by the FDA last year and re-filed.

• AZ boosts cardio-renal portfolio with $2.7bn ZS Pharma buy

  Buying ZS Pharma gives the UK pharma major rights to potassium-binding compound ZS-9 (sodium zirconium cyclosilicate), which it describes as a "potential best-in-class" treatment for hyperkalaemia with